Merck's HPV vaccine is most effective among youths
May 24 2005 12:00 AM ET
An experimental vaccine developed by Merck to prevent the sexually transmitted human papillomavirus, which has been linked with virtually all cases of cervical cancer, is slightly more effective in young people than in older recipients, The Wall Street Journal reports. Merck officials said the vaccine, called Gardasil, produced a higher anti-HPV immune response on boys and girls ages 10-15 than in a group of women ages 16-23. The younger group had a 100% antibody response rate to three common strains of HPV after being vaccinated, and a 99.9% rate to a fourth strain; the older women had a 100% response rate to the first three strains, and a 99.1% response rate to the fourth.
A previous study showed Gardasil reduced the incidence of HPV infections by 90% in a study of more than 500 women. In addition to being linked with cervical cancer, HPV infections can cause genital and anal warts in both men and women, and has been shown in some studies to boost the risk of anal cancer.
Merck officials say they will seek Food and Drug Administration approval of the vaccine later this year.
- Reba McEntire: First Time I Saw a Reba Drag Queen 'It Really Ticked Me Off'
- Ted Cruz/OUT NYC Fallout: Broadway Cares Cancels Benefit at Hotel
- Bruce Jenner Ends Speculation, Comes Out as Transgender Woman
- Op-ed: Michfest's Founder Chose to Shut Down Rather Than Change With the Times
- AIDS Org. Made Men Over 40 Pay to Attend Pool Party
- Gay High-Schooler Gets Date for Prom — With Straight Best Friend